Literature DB >> 24560700

Development of antiviral agents toward enterovirus 71 infection.

Hamid Reza Pourianfar1, Lara Grollo2.   

Abstract

Enterovirus 71 (EV71) infection remains a public health problem at a global level, particularly in the Asia-Pacific region. The infection normally manifests as hand-foot-mouth disease; however, it is capable of developing into potentially fatal neurological complications. There is currently no approved vaccine or antiviral substance available for the prevention or treatment of EV71 infection. This paper, thus, reviews efforts to develop or discover synthetic as well as naturally occurring compounds directed against EV71 infection. The recent achievements in cellular receptors of EV71 are also highlighted, and their contribution to the development of antiviral drugs against EV71 is discussed in this article.
Copyright © 2013. Published by Elsevier B.V.

Entities:  

Keywords:  Antiviral agents; EV71 infection; EV71 receptors; Phytochemicals

Mesh:

Substances:

Year:  2014        PMID: 24560700     DOI: 10.1016/j.jmii.2013.11.011

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  8 in total

1.  Antibodies to P-selectin glycoprotein ligand-1 block dendritic cell-mediated enterovirus 71 transmission and prevent virus-induced cells death.

Authors:  Xiao-Xin Ren; Chuan Li; Si-Dong Xiong; Zhong Huang; Jian-Hua Wang; Hai-Bo Wang
Journal:  Virulence       Date:  2015-09-23       Impact factor: 5.882

2.  Optimization of a Class of Tryptophan Dendrimers That Inhibit HIV Replication Leads to a Selective, Specific, and Low-Nanomolar Inhibitor of Clinical Isolates of Enterovirus A71.

Authors:  Eva Rivero-Buceta; Liang Sun; Belén Martínez-Gualda; Elisa G Doyagüez; Kim Donckers; Ernesto Quesada; María-José Camarasa; Leen Delang; Ana San-Félix; Johan Neyts; Pieter Leyssen
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

3.  Antiviral Activity of a Llama-Derived Single-Domain Antibody against Enterovirus A71.

Authors:  Peng-Nien Huang; Hsiang-Ching Wang; Hui-Chen Hung; Sung-Nien Tseng; Teng-Yuan Chang; Min-Yuan Chou; Yu-Jen Chen; Yun-Ming Wang; Shin-Ru Shih; John Tsu-An Hsu
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

4.  The correlation between the presence of viremia and clinical severity in patients with enterovirus 71 infection: a multi-center cohort study.

Authors:  Hao-Yuan Cheng; Yi-Chuan Huang; Ting-Yu Yen; Shao-Hsuan Hsia; Yu-Chia Hsieh; Chung-Chen Li; Luan-Yin Chang; Li-Min Huang
Journal:  BMC Infect Dis       Date:  2014-07-29       Impact factor: 3.090

Review 5.  Enterovirus-Associated Hand-Foot and Mouth Disease and Neurological Complications in Japan and the Rest of the World.

Authors:  Gabriel Gonzalez; Michael J Carr; Masaaki Kobayashi; Nozomu Hanaoka; Tsuguto Fujimoto
Journal:  Int J Mol Sci       Date:  2019-10-20       Impact factor: 5.923

6.  Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.

Authors:  Dilip K Tosh; Kiran S Toti; Brett L Hurst; Justin G Julander; Kenneth A Jacobson
Journal:  Bioorg Med Chem Lett       Date:  2020-10-05       Impact factor: 2.823

Review 7.  A literature review and case report of hand, foot and mouth disease in an immunocompetent adult.

Authors:  Carlos Omaña-Cepeda; Andrea Martínez-Valverde; María del Mar Sabater-Recolons; Enric Jané-Salas; Antonio Marí-Roig; José López-López
Journal:  BMC Res Notes       Date:  2016-03-15

8.  Enterovirus Inhibition by Hinged Aromatic Compounds with Polynuclei.

Authors:  Jih Ru Hwu; Avijit Panja; Srinivasan Jayakumar; Shwu-Chen Tsay; Kui-Thong Tan; Wen-Chieh Huang; Yu-Chen Hu; Pieter Leyssen; Johan Neyts
Journal:  Molecules       Date:  2020-08-22       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.